Loading...
XNAS
SIGA
Market cap251mUSD
Jul 09, Last price  
3.50USD
1D
-1.13%
1Q
-19.72%
Jan 2017
21.53%
Name

SIGA Technologies Inc

Chart & Performance

D1W1MN
XNAS:SIGA chart
P/E
10.77
P/S
2.65
EPS
0.32
Div Yield, %
17.14%
Shrs. gr., 5y
-2.05%
Rev. gr., 5y
-5.41%
Revenues
95m
-31.80%
7,257,5326,698,7178,065,61813,811,85819,215,83712,725,7928,970,8355,519,3003,139,8358,175,87814,987,62812,268,960477,053,78226,742,085124,959,304133,670,454110,775,610139,917,220138,719,35094,600,000
Net income
23m
-60.65%
-9,898,708-5,638,557-8,599,377-17,617,939-28,195,33913,594,176-14,528,153-17,177,333-265,463,138-39,451,324-39,697,960-36,235,484421,807,828-7,241,14756,342,01069,450,76633,904,80668,068,82659,214,21623,300,000
CFO
43m
-10.85%
-4,438,005-5,447,833-7,197,886-8,470,829-10,825,38425,574,036-20,222,82658,436,50214,176,52011,109,383-115,590,781-8,158,29868,871,323-18,204,30371,519,22811,494,63641,611,06294,799,33148,761,80743,471,453
Dividend
Apr 29, 20250.6 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.
URL
https://www.siga.com/
IPO date
Sep 09, 1997
Employees
39
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT